News and Trends 4 Sep 2015
Gut bacteria growth time can cause disease?
A method of profiling bacterial growth time in the gut's microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came…
Diabetes
- Latest Posts
News and Trends 2 Sep 2015
Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant
Novo Nordisk has acquired two small Indiana based research Biotechs, Calibrium and MB2, as part of its strategy to establish itself in the US as a major Diabetes research giant.…
News and Trends 31 Aug 2015
When Tech and Biotech merge, Google and Sanofi partner up to revolutionize Diabetes Management
Taking care of diabetes is still far too complex currently. In future, Sanofi and Google will jointly take care of this problem, hoping to ease the life of millions of…
News and Trends 26 Aug 2015
Ouch! Novo Nordisk fails in Phase III
Novo Nordisk joins UCB and gets knocked down by its drug's final clinical trial. Liraglutide, the already approved adjunct therapy for people with type 2 diabetes won't reach out to…
ADVERTISEMENT
News and Trends 3 Aug 2015
Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline
Olivier Brandicourt, new CEO of Sanofi since last April, has been interviewed by EuroBusiness Media on the company's last results. The successor of Chris Viehbacher took the opportunity to show the…
News and Trends 7 Jul 2015
Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment
Novo Nordisk cancels its collaboration deal with Zosano Pharma. The diabetes drug semaglutine won’t be delivered with the microneedle patch technology, developed from the latter. Zosano’s patch technology uses thin…
News and Trends 1 Jul 2015
Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?
Adocia and Eli Lilly completed an impressive Phase Ib clinical trial evaluating BioChaperone Lispro, a treatment designed to accelerate insulin absorption. The study aimed to compare BioChaperone Lispro to Lilly’s…
News and Trends 11 Jun 2015
Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes
Hundreds of millions of people all over the word suffer from type 2 Diabetes and the competition between pharma companies is fierce. Amongst them, Sanofi must think that good things…
News and Trends 29 May 2015
Poxel is Looking towards Japan’s Lucrative Diabetes Market
Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate.…
News and Trends 17 May 2015
The Miracle Berry which Hacks your Taste Buds to Replace Sugar
Can you name a fruit capable of disturbing your taste buds? For up to two hours, the red miracle berry can transform sour foods like lemon or vinegar, in an amazing sweet…
ADVERTISEMENT
News and Trends 3 May 2015
After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug
Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with an incredible jump of +100% on its third day as…
News and Trends 15 Apr 2015
AstraZeneca avoided a public crisis of its marketed diabetes treatment
Last week, FDA expressed its concerns about AstraZeneca’s treatment for type 2 diabetes, Onglyza. According to Reuters, FDA found “significant or near significant” increase of death risk. However, the agency…
News and Trends 13 Mar 2015
Orgenesis acquires MaSTherCell
Orgenesis acquired MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics based in Gosselies, Belgium, as part of the American company’s plan to increase its global presence and capabilities.…
News and Trends 27 Feb 2015
Sanofi: Get Ready for the Launch of the First Inhaled Insulin in the U.S.
Sanofi, the global healthcare leader has core strengths in the field of healthcare due to its seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal…
News and Trends 21 Feb 2015
Succesfull Phase II for Novo Nordisk’s new diabetes treatment
Good news for diabetes mellitus type 2 patients, as Novo Nordisk announced positive results for phase II trial with oral semaglutide. Novo Nordisk successfully completed the phase II trial for…
News and Trends 4 Nov 2014
Novo Nordisk invests €104M in new laboratory for Diabetes
Danish insulin giant Novo Nordisk has made a 104 million euros investment in new laboratories at the company’s research and development campus. Based in Malov in Denmark, the lab is expected…
ADVERTISEMENT
News and Trends 8 Oct 2014
Once a Week Insulin Shot : Novo Nordisk’s new Idea
Denmark's Novo Nordisk, the world's largest insulin seller, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world's first once-weekly…
News and Trends 16 Sep 2014
The first insulin biosimilar has been approved in Europe
The European Commission granted marketing authorisation to Eli Lilly and Company and Boehringer Ingelheim for the first insulin biosimilar glargine product. It is indicated to treat diabetes in adults, adolescents…
News and Trends 26 Aug 2014
Adocia launches a Phase III in India for its Diabetic Foot Ulcer treatment
Adocia announced today the initiation of a clinical Phase III study in India of BioChaperone PDGF-BB, the company’s innovative formulation of Platelet Derived Growth Factor (PDGF-BB) for the treatment of…
News and Trends 25 Aug 2014
KalVista start the clinical development of a new treatment for diabetic macular edema
KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma…
